RxDoctor Payments Data

Vinh Doan, MD

Family Medicine · Murrells Inlet, SCNPI 1265927792

Payments from drug & device makers

$2,899in general payments, 2019–2025

Across 154 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$930
  • AbbVie$341
  • Lilly USA, LLC$330
  • GSK$167
  • Pfizer$166
  • Exact Sciences$163
  • plus $803 from 15 others

What the payments were for

  • Food & beverage$2,86799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,899 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$251,660
Medicare patients
500
Services billed
7,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide170$258,923
JakafiRuxolitinib Phosphate13$219,417
EliquisApixaban122$168,601
JardianceEmpagliflozin87$89,070
MounjaroTirzepatide53$78,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$70,295
EntrestoSacubitril/Valsartan25$47,820
FarxigaDapagliflozin Propanediol25$37,460
TrulicityDulaglutide17$29,737
Repatha SureclickEvolocumab27$16,735
MyrbetriqMirabegron12$16,714
JanuviaSitagliptin Phosphate11$14,492
Tresiba Flextouch U-100Insulin Degludec11$12,408
HorizantGabapentin Enacarbil12$12,245
RybelsusSemaglutide11$11,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$930$270,798181 claims
PfizerEliquis$166$168,601122 claims
Lilly USA, LLCMounjaro, Trulicity$330$107,85170 claims
Boehringer IngelheimJardiance$19$89,07087 claims
GSKTrelegy Ellipta$167$70,29570 claims
NovartisEntresto$82$47,82025 claims
AstraZenecaFarxiga, Symbicort$143$45,17639 claims
AbbVieSynthroid$341$3,39546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →